Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel®
Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel®
The overall objective of the study was to describe the long-term effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting.
Inclusion Criteria:
Presence of psoriasis or previous evidence of psoriasis documented by a dermatologist as part of usual care
At least one of the following forms of psoriatic arthritis (PsA):
Active psoriatic arthritis at the time of the study enrollment
Patients must demonstrate greater than 3 swollen joints and greater than 3 tender/painful joints
Greater than 18 years of age at the time of consent
Able to start etanercept therapy per the approved product monograph
Informed consent must be provided before any study specific procedures are performed
Exclusion Criteria:
Active infections at time of initiating Enbrel® therapy
Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the study medication
A malignancy, other than basal cell carcinoma of the skin or, in situ carcinoma of the cervix, within the past 5 years
Known hypersensitivity to etanercept or any of its components
Patients receiving, or who have received:
Patients receiving or who have received etanercept
Treatment with any investigational therapy in the 30 days prior to enrollment or during the study
Active guttate, erythrodermic or pustular psoriasis at the time of screening
Presence of any significant and uncontrolled medical condition, which in the Investigator's opinion, precludes the use of etanercept as outlined in the product monograph
Sepsis or at risk of septic syndrome
Patients not available for follow-up assessment
Concerns for subject's compliance with the protocol procedures